Mankind Pharma Limited — Investor Meet, 26-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Mankind Pharma posted solid Q4 FY26 revenue of ₹3,443 Cr (+11.8% YoY) & FY26 revenue of ₹14,278 Cr (+17% YoY). Q4 Adjusted EBITDA margin rose to 27.1%, with PAT up 30.4% to ₹559 Cr. Domestic business saw robust growth, driven by chronic therapies (now ~40% contribution).

Management projects FY27 top-line growth to be double-digit (outperforming IPM) and EBITDA margins of 25.5-26.5%. The strategy prioritizes specialty chronic therapies and R&D, with a new biotech facility investment. While GLP-1 pens are launched, the company takes a cautious, long-term approach to market competitiveness. Confidence is high for a stronger FY27.